KRISTINE MIMS: Open Payments
NPI 1164092532 · CICERO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,563 in 133 payments from 15 companies in 2025. Trend: 2023 $2,702 · 2024 $1,933 · 2025 $2,563
Food & beverage: $2,563
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $507 |
| Teva Pharmaceuticals USA, Inc. | 23 | $430 |
| E.R. Squibb & Sons, L.L.C. | 16 | $344 |
| Vanda Pharmaceuticals Inc. | 9 | $277 |
| Alkermes, Inc. | 15 | $230 |
| Neurocrine BioSciences, Inc. | 11 | $204 |
| Otsuka America Pharmaceutical, Inc. | 11 | $194 |
| ABBVIE INC. | 10 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Lundbeck LLC | 2 | $41 |
Products named: CAPLYTA, AUSTEDO XR, COBENFY, ARISTADA, INGREZZA, VRAYLAR, HETLIOZ, REXULTI.
Industry payments across NY — which companies pay providers there.
